Merck Completes Acquisition of Terns Pharmaceuticals, Inc.
Addition of TERN-701, a novel investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor, further diversifies Merck's oncology pipeline
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the acquisition of Terns Pharmaceuticals, Inc. ("Terns") (NASDAQ:TERN).
"The Terns acquisition reflects Merck's continued focus on science‑driven, value‑enhancing business development aimed at bringing meaningful innovation to patients," said Robert M. Davis, chairman and chief executive officer, Merck. "We believe TERN‑701 has the potential to become a differentiated treatment option for certain patients with chronic myeloid leu
